[RALEIGH, N.C.] — Merz Aesthetics celebrates 15 years since its flagship brand XEOMIN was first approved for aesthetic use by the U.S. Food and Drug Administration (FDA).
XEOMIN is a double-purified neurotoxin, FDA approved for the simultaneous treatment of upper facial lines, like forehead lines, frown lines and crow’s feet. To celebrate this 15-year U.S. milestone, 15 lucky winners will receive a year of free XEOMIN treatments through Xperience+ by Merz Aesthetics U.S. patient loyalty program.
Neurotoxins are all the rage in aesthetics right now, as the quiet luxury movement leans on aesthetic solutions that are natural-looking and preserve the integrity of facial movement.
Additionally, Merz Aesthetics is also launching a new, refreshed multi-channel campaign for XEOMIN in celebration of the milestone. Containing only three ingredients, XEOMIN is the first and only double-purified treatment with XTRACT Technology, clinically proven to smooth upper facial lines for natural-looking results.
“Since its debut, XEOMIN has been a trusted choice for patients and providers seeking effective, natural-looking results,” Patrick Urban, president, North America, Merz Aesthetics, says in a quote to BUSINESS WIRE. “Celebrating 15 years is more than a milestone — it’s a testament to our unwavering commitment to proven performance and advancing aesthetic care.”
It's worth nothing that with XEOMIN, no patients in pivotal clinical studies developed treatment resistance due to neutralizing antibodies.
“Leveraging our proprietary XTRACT Technology manufacturing process, we have established ourselves as a pioneer in neurotoxins, delivering outcomes and efficacy that both patients and providers expect,” adds Dr. Samantha Kerr, chief scientific officer of Merz Aesthetics. “We’re committed to driving continued innovation for years to come.”
